8-K current report · filed Nov 5, 2026

CASTLE BIOSCIENCES INC (CSTL) 8-K Current Report: November 5, 2026

Item 2.02Item 7.01Item EX-99.1Item EX-99.2CSTL overview

Short answer

CASTLE BIOSCIENCES INC (CSTL) filed an 8-K current report with the SEC on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2). Q3 2026 financial results for the quarter ended September 30, 2026.

CASTLE BIOSCIENCES INC 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Q3 2026 financial results for the quarter ended September 30, 2026
  • Press release Exhibit 99.1 contains the underlying results and management commentary
  • Investor focus: revenue growth, profitability, cash use, and updated outlook in the exhibit

Item 7.01 · Regulation FD Disclosure

  • Investor presentation released November 5, 2026 under Regulation FD
  • Slides may guide management discussions in future investor meetings
  • Presentation content in Exhibit 99.2, relevant for updated company messaging and disclosures

Item EX-99.1 · Exhibit EX-99.1

  • Q3 revenue $102.9M, up 24% YoY, led by TissueCypher reports up 47% to 15,574
  • 2026 revenue guidance raised to $385M-$395M from $365M-$375M, signaling stronger near-term demand
  • Adjusted EBITDA $12.7M versus $9.2M, while GAAP net loss widened to $4.1M from $0.5M
  • Nine-month operating cash flow fell to $12.8M from $37.4M, despite $277.7M in cash and marketable securities
  • Positive Adjusted EBITDA maintained as target for Q4 2026, full-year 2026 and full-year 2027

Item EX-99.2 · Exhibit EX-99.2

  • Q3 2026 revenue $102.9M, total test volume 32,431, adjusted EBITDA $12.7M, and adjusted gross margin 77%
  • Full-year 2026 revenue guidance raised to $385M-$395M, up $45M at the midpoint since February
  • Management expects positive adjusted EBITDA in Q4 and full-year 2026, marking a near-term profitability milestone
  • TissueCypher volumes rose 47% year over year to 15,574, offsetting lower DecisionDx-Melanoma and DecisionDx-SCC volumes
  • Cash and marketable securities totaled $277.7M at September 30, supporting commercial expansion, evidence generation, and disciplined capital allocation

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other CASTLE BIOSCIENCES INC 8-K filings

Get the next CSTL 8-K as it lands

Follow CSTL for push alerts, or ask the research agent what this filing means.